Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 8/20 | 0.85 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.85 |
| ▸ | USP5 | P45974 | 1/20 | 0.85 |
| ▸ | STAT3 | P40763 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | RGS12 | O14924 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315703 | 1.00 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315701 | 1.00 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315700 | 1.00 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1317671 | 0.92 | USP9X (1.00) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1317669 | 0.92 | USP9X (1.00) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1317674 | 0.92 | USP9X (1.00) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL882501 | 0.92 | USP9X (1.00) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315734 | 0.91 | USP9X (0.81) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315735 | 0.91 | USP9X (0.81) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315733 | 0.91 | USP9X (0.81) | USP9XUCHL1USP5STAT3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096499-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096499-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-06 | — | — | US | disclosed |
| US-8648102-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648102-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130244986-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244986-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-8450337-B2 | Methods of treating skin disorders with caffeic acid analogs | MOLECULIN, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450337-B2 | Methods of treating skin disorders with caffeic acid analogs | MOLECULIN, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2011069141-A2 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100292229-A1 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292229-A1 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-18 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | MOLECULIN, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2008005954-A2 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2005058829-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292229-A1 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, STAT3, MYCBP | USP9X 4451/4885UCHL1 4077/4885USP5 3468/4885 |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | CUTA, TYR, PPARA | USP9X 4553/4885UCHL1 3330/4885USP5 3332/4885 |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | USP9X 3371/4885UCHL1 3672/4885USP5 3228/4885 |
| US-20130244986-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | CUTA, TYR, PPARA | USP9X 4553/4885UCHL1 3330/4885USP5 3332/4885 |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | USP9X 3371/4885UCHL1 3672/4885USP5 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.